Russell, Holly
Kedzierska, Katarzyna
Buchanan, Daniel D.
Thomas, Rachael
Tham, Emma
Mints, Miriam
Keränen, Anne
Giles, Graham G.
Southey, Melissa C.
Milne, Roger L.
Tomlinson, Ian
Church, David
Spurdle, Amanda B.
O’Mara, Tracy A.
Lewis, Annabelle http://orcid.org/0000-0003-1876-1927
Funding for this research was provided by:
Medical Research Council (MR/P000738/1)
Wellcome Trust (090532/Z/09/Z)
National Health and Medical Research Council (APP1111246)
CRUK (C26642/A27963)
National Health and Medical Research Council (APP1061779)
Region Stockholm
Article History
Received: 25 March 2020
Accepted: 23 June 2020
First Online: 8 July 2020
Change Date: 1 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13148-021-01058-w
Ethics approval and consent to participate
: ANECS: The study was approved by the QIMR Berghofer Medical Research Institute Human Research Ethics Committee and the participating hospitals and cancer registries. All participants provided informed written consent.RENDOCAS<i>:</i> The study was approved by the Regional Ethical Review Authority in Stockholm, Sweden. The original registration number was 2010/1536-31/2 with additions 2014/1294-32 and 2014/1325-32. All patients provided written informed consent.MCCS: All MCCS participants gave informed consent and the study was approved by the Cancer Council Victoria Human Research Ethics Committee.
: Not applicable
: DDB served as a consultant on the Tumour Agnostic (dMMR) Advisory Board of Merck Sharp and Dohme in 2017 and 2018 for Pembrolizumab. The other authors declare that they have no competing interests